Bioatla announces pricing of initial public offering

San diego, dec. 15, 2020 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial...
BCAB Ratings Summary
BCAB Quant Ranking